A database of FDA approved therapeutic peptides and proteins
| This page displays user query in tabular form. |
1768 details |
| Primary information | |
|---|---|
| ThPP ID | Th1186 |
| Therapeutic Peptide/Protein Name | Human rabies virus immune globulin |
| Sequence | NA view full sequnce in fasta |
| Functional Classification | IIIa |
| Molecular Weight | NA |
| Chemical Formula | NA |
| Isoelectric Point | NA |
| Hydrophobicity | NA |
| Melting Point (℃) | NA |
| Half Life | NA |
| Description | NA |
| Indication/Disease | It is indicated for individuals suspected of exposure to rabies, particularly severe exposure, with one exception: persons who have been previously immunized with HDCV Rabies Vaccine in a pre-exposure or postexposure treatment series should receive only vaccine. |
| Pharmacodynamics | NA |
| Mechanism of Action | It provides passive protection by neutralizing the rabies virus when given to individuals exposed to rabies virus. When a rabies immune globulin dose of 20 IU/kg was given simultaneously with the first dose of rabies vaccine, levels of passive anti-rabies antibody were detected 24 hours after injection in all individuals. There was minimal or no interference with the immune response to the initial and subsequent doses of rabies vaccine, including booster doses. |
| Toxicity | NA |
| Metabolism | NA |
| Absorption | NA |
| Volume of Distribution | NA |
| Clearance | NA |
| Categories | NA |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | Live virus vaccines, such as measles vaccine, should not be given for four months following Human rabies virus immune globulin administration because antibodies in the immune globulin preparation may interfere with the immune response to the vaccine. |
| Target | NA |
| Information of corresponding available drug in the market | |
| Brand Name | Hyperab Rabies Immune Globulin Human |
| Company | Cutter Med & Biol, Division Of Miles Canada Ltd. |
| Brand Discription | |
| Prescribed for | |
| Chemical Name | |
| Formulation | 16.50% |
| Physcial Appearnce | Liquid |
| Route of Administration | intramuscular |
| Recommended Dosage | The recommended dose for HyperRAB S/D is 20 IU/kg (0.133 mL/kg) of body weight given preferably at the time of the first vaccine dose |
| Contraindication | Hypersensitivity |
| Side Effects | Fever, pain, soreness, tenderness, or stiffness at the injection site, Skin rash |
| Useful Link | https://www.drugs.com/ |
| PubMed ID | 10675760 |
| 3-D Structure | N.A. |